What is Lincoln Pharmaceuticals Ltd (LINCOLN) share price return in the past 10 years?

Lincoln Pharmaceuticals Ltd share price has appreciated 9.3% annually (CAGR) over the past ten years.

What is the share price of Lincoln Pharmaceuticals Ltd (LINCOLN)?

Company share prices are keep on changing according to the market conditions. The current trading price of Lincoln Pharmaceuticals Ltd (LINCOLN) on 25-Sep-2026 16:59:59 at 16:59 is 590.40.

What is the P/E ratio of Lincoln Pharmaceuticals?

The latest standalone P/E ratio of Lincoln Pharmaceuticals as of 25-Sep-2026 is 12.26.

What is the P/B ratio of Lincoln Pharmaceuticals Ltd (LINCOLN)?

The latest standalone P/B ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) as of 25-Sep-2026 is 1.49.

What is the 52-week high and low of Lincoln Pharmaceuticals Ltd (LINCOLN)?

The 52-week high of Lincoln Pharmaceuticals Ltd (LINCOLN) is Rs. 770.00 and the 52-week low is Rs. 439.95.

Lincoln Pharmaceuticals Ltd (LINCOLN)

Name: Lincoln Pharmaceuticals Ltd (LINCOLN)
Brand: Lincoln Pharmaceuticals

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

₹590.40 -5.20 (-0.87%)

As on 25-Sep'26 16:59

Lincoln Pharmaceuticals Ltd (LINCOLN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

₹590.40 -5.20 (-0.87%)

As on 25-Sep'26 16:59

Key Metrics

Valuation Multiples

Market Cap

₹1,183 Cr.

Current Price

₹590.4

52-Week Low / High

₹440 / 770

TTM EPS

₹48.2

TTM Sales

₹694 Cr.

Book Value per Share

₹396.3

P/E Ratio

12.26

In line with its 5-year historical median

Industry PE

54.9

Price to Book (P/B)

1.49

Lower than its 5-year historical median

Price to Sales (P/S)

1.70

In line with its 5-year historical median

EV/EBITDA

8.03

In line with its 5-year historical median

Dividend Yield

0.3%

Profitability Efficiency

Return on Equity (ROE)

13.02%

Outperforms industry median

Return on Capital Employed (ROCE)

17.55%

Outperforms industry median

Return on Assets (ROA)

10.64%

Operating Profit Margin

16.3%

Net Profit Margin

13.21%

Gross Profit Margin

18.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

7.35%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

1.58%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-11.74%

Asset Quality

Promoter Holding

49.78%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹774 Cr.

Equity

₹20 Cr.

Face Value

₹10

All Time Low / High

₹8.05 / 975.00

Lincoln Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Lincoln Pharmaceuticals Ltd a good quality company?

Lincoln Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Lincoln Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Lincoln Pharmaceuticals Ltd vs industry peers?

Lincoln Pharmaceuticals Ltd revenue CAGR is 10.03%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Lincoln Pharmaceuticals Ltd?

Promoters hold 49.78% of the Lincoln Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Lincoln Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 9.1% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	19.8%	18.6%	18.3%	21.7%	21.8%	25.2%	24.3%	21.8%	22.5%	17.6%	-
Value Creation Index ⓘ	0.4	0.3	0.3	0.6	0.6	0.8	0.7	0.6	0.6	0.3	-
Growth Parameters ⓘ
Sales ⓘ	311	304	325	353	376	423	472	510	581	623	694
Sales YoY Gr.	-	-2.1%	6.8%	8.6%	6.5%	12.5%	11.6%	8.1%	13.8%	7.4%	-
Adj EPS ⓘ	12.2	13.6	15.1	21.8	21.6	30.7	33.9	32.3	44.5	37.4	48.2
YoY Gr.	-	11.8%	10.8%	44.5%	-0.9%	42.1%	10.5%	-4.7%	37.6%	-15.9%	-
BVPS (₹) ⓘ	80.4	94.8	109.8	131.3	152.3	182.9	216.1	250.9	296	335.3	396.3
Adj Net Profit ⓘ	19.9	27.2	30.2	43.6	43.2	61.5	68	64.8	89.1	75	96
Cash Flow from Ops. ⓘ	28.9	17.8	21.3	51.1	70.7	69.4	76.2	39.2	63.2	93	-
Debt/CF from Ops. ⓘ	2.1	3	2.6	0.7	0.1	0	0	0.1	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8%	10.6%	9.7%	7.4%
Adj EPS ⓘ	13.3%	11.6%	3.4%	-15.9%
BVPSⓘ	17.2%	17.1%	15.8%	13.3%
Share Price	9.3%	8.9%	5.3%	9.8%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	15.9	16.6	14.8	18.1	15.2	18.3	17	13.9	16.3	11.9	13.2
Op. Profit Mgn % ⓘ	10.6	14	14.2	17.1	15.9	20.6	20.3	17.5	17.3	16.3	14.6
Net Profit Mgn % ⓘ	6.4	9	9.3	12.4	11.5	14.6	14.4	12.7	15.4	12	13.9
Debt to Equity ⓘ	0.5	0.3	0.3	0.1	0	0	0	0	0	0	-
Working Cap Days ⓘ	168	198	221	223	227	227	226	231	224	232	110
Cash Conv. Cycle ⓘ	93	93	94	90	80	63	64	79	85	76	81

Valuation of Lincoln Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	400	360	361	366	386	424	472	510	581	623
Operating Expenses ⓘ +	360	314	308	299	321	337	377	421	481	522
Manufacturing Costs	41	35	59	68	72	69	78	96	114	133
Material Costs	255	203	156	136	138	156	170	179	204	203
Employee Cost	29	38	51	52	59	63	80	93	103	112
Other Costs ⓘ	35	38	42	43	52	49	50	53	60	73
Operating Profit ⓘ	41	47	52	67	66	87	95	89	100	101
Operating Profit Margin (%)	10.1%	13.0%	14.5%	18.4%	17.0%	20.6%	20.2%	17.5%	17.2%	16.3%
Other Income ⓘ +	7	3	5	6	11	6	10	22	34	22
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	10	7	5	4	2	2	1	2	1	2
Depreciation ⓘ	5	6	6	7	7	8	8	9	11	13
Profit Before Tax ⓘ	33	37	46	62	67	84	96	100	122	109
Tax ⓘ	9	9	12	13	16	21	27	28	29	27
Profit After Tax	24	28	35	49	51	62	69	73	93	82
PAT Margin (%)	6.0%	7.8%	9.6%	13.3%	13.3%	14.7%	14.7%	14.3%	16.1%	13.2%
Adjusted EPS (₹)	14.5	14.1	17.3	24.4	25.7	31.1	34.6	36.4	46.6	41.1
Dividend Payout Ratio (%)	6.90%	8.50%	8.70%	6.20%	5.80%	4.80%	4.30%	4.10%	3.90%	4.40%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	133	192	224	269	313	366	433	502	593	672
Share Capital ⓘ	16.31	20	20	20	20	20.03	20.03	20.03	20.03	20.03
Reserves ⓘ	117	172	204	249	293	346	413	482	573	652
Debt +	76	57	55	32	5	0	2	2	1	0
Long Term Debt	24	12	7	2	1	0	0	0	0	0
Short Term Debt	53	45	49	30	4	0	2	2	1	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	30	32	43	44	51	57	72	51	72	85
Others Liabilities ⓘ	35	41	40	53	67	64	48	81	59	65
Total Liabilities ⓘ	275	324	363	399	437	487	555	637	725	822
Fixed Assets
Net Fixed Assets ⓘ +	98	103	117	121	123	111	132	151	179	182
Gross Block	121	108	128	138	147	142	171	197	237	252
Accumulated Depreciation	22	5	11	17	24	31	39	47	57	70
CWIP ⓘ	3	7	0	2	0	2	16	7	3	4
Investments ⓘ	0	10	11	18	34	81	97	91	139	174
Inventories	27	37	45	36	47	47	73	70	77	79
Trade Receivables	81	91	109	122	101	113	116	136	162	166
Cash Equivalents	13	12	15	8	15	14	19	34	14	22
Others Assets ⓘ	53	65	66	91	116	120	102	147	151	194
Total Assets ⓘ	275	324	363	399	437	487	555	637	725	822

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	45	25	27	53	75	69	76	39	63	93
PBT ⓘ	33	37	46	62	67	84	96	100	122	109
Adjustment ⓘ	14	11	12	9	9	5	1	-0	-17	1
Changes in Working Capital ⓘ	5	-13	-22	-1	14	0	2	-31	-16	9
Tax Paid ⓘ	-7	-10	-9	-18	-15	-19	-24	-30	-26	-26
Cash Flow From Investing Activity ⓘ +	-42	-25	-12	-18	-31	-64	-78	-37	-57	-79
Capex	-34	-18	-10	-15	-7	-9	-45	-14	-40	-19
Net Investments	-1	-10	0	-6	-14	-44	-23	-4	-3	-30
Others ⓘ	-7	2	-2	3	-9	-11	-9	-19	-15	-30
Cash Flow From Financing Activity ⓘ +	-3	0	-11	-36	-38	-6	-3	-5	-5	-6
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	2	-6	-7	-9	-2	-1	-1	0	0	0
Interest Paid ⓘ	-11	-7	-5	-4	-2	-1	-1	-1	-1	-2
Dividend Paid ⓘ	-2	-2	-3	-4	-7	0	-3	-3	-3	-4
Others ⓘ	8	15	4	-18	-26	-4	2	-0	-1	-1
Net Cash Flow ⓘ	-0	-0	3	-1	7	-1	-5	-2	1	8

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	19.49	17.29	16.63	19.75	17.67	18.32	17.35	15.59	17.04	13.02
ROCE (%)	21.18	18.51	19.05	22.5	22.3	24.9	24.29	21.82	22.53	17.55
Asset Turnover Ratio	1.51	1.22	1.05	0.99	0.96	0.95	0.95	0.9	0.89	0.84
PAT to CFO Conversion(x)	1.88	0.89	0.77	1.08	1.47	1.11	1.1	0.53	0.68	1.13
Working Capital Days
Receivable Days	89.70	85.50	101	112.20	102.20	89.30	84.30	86.10	89.60	91.80
Inventory Days	22.20	32.40	41.70	39.50	38.20	39.10	43.90	48.70	44.30	43.60
Payable Days	54.20	56.50	88.50	117.60	125.80	126.80	138.40	124.60	110.30	141.70

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

The current trading price of Lincoln Pharma on 25-Sep-2026 16:59 is ₹590.4.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Lincoln Pharma stood at ₹1,182.6 Cr

The latest P/E ratio of Lincoln Pharma as of 24-Sep-2026 is 12.26.

The latest P/B ratio of Lincoln Pharma as of 24-Sep-2026 is 1.49.

The 52-week high of Lincoln Pharma is ₹770.0 and the 52-week low is ₹439.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lincoln Pharma is ₹694 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lincoln Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Lincoln Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Lincoln Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals was established in 1979 to manufacture and market affordable therapeutic products. Since then, Lincoln Pharmaceuticals has come a long way.

Lincoln Pharmaceuticals is a public limited company with a large shareholder base including members of the medical fraternity. It has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.

An ultramodern laboratory with state-of-the-art equipments ensures in-house quality assurance of each of the products. The products are designed for all therapeutic segments with a special emphasis on gynecological and orthopedic specialties.

Group of Companies

Lincoln Parenterals
Karnavati Distributors
Down Town Travels
Shelavi Paper Mills

Product of the company

Tablets
Capsules
Injectables
Syrups
Ointments

Certification

WHO-GMP standard
ISO 9002 certification
Export House certification

You have 45 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Lincoln Pharma - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Lincoln Pharma - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

What is the share price of Lincoln Pharma?

What is the market cap of Lincoln Pharma?

What is the P/E ratio of Lincoln Pharma?

What is the P/B ratio of Lincoln Pharma?

What is the 52-week high and low of Lincoln Pharma?

What is the TTM revenue of Lincoln Pharma?

Is Lincoln Pharmaceuticals Ltd a good quality company?

Is Lincoln Pharmaceuticals Ltd undervalued or overvalued?

Is Lincoln Pharmaceuticals Ltd a good buy now?

About Lincoln Pharmaceuticals Ltd